Larry W Markham1, Jonathan H Soslow2, Aryaz Sheybani3, Kim Crum3, Frank J Raucci4, William B Burnette5. 1. Division of Pediatric Cardiology, Department of Pediatrics, Riley Hospital for Children and Indiana University School of Medicine, Indianapolis, IN, USA. 2. Division of Pediatric Cardiology, Department of Pediatrics, Monroe Carell Jr. Children's Hospital, Nashville, TN, USA. Jonathan.h.soslow@vumc.org. 3. Division of Pediatric Cardiology, Department of Pediatrics, Monroe Carell Jr. Children's Hospital, Nashville, TN, USA. 4. Division of Pediatric Cardiology, Department of Pediatrics, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA, USA. 5. Division of Pediatric Neurology, Department of Pediatrics, Monroe Carell Jr. Children's Hospital, Nashville, TN, USA.
Abstract
BACKGROUND: Cardiomyopathy is the leading cause of death in Duchenne muscular dystrophy (DMD), but studies suggest heart failure biomarkers correlate poorly with cardiomyopathy severity. DMD clinical trials have used troponin I (cTnI) as a biomarker of toxicity, but it is unclear if asymptomatic DMD patients have elevated cTnI. We longitudinally evaluated cTnI, brain natriuretic peptide (BNP), and N-terminal pro-BNP (NT-proBNP) in a DMD cohort. METHODS: DMD patients were prospectively enrolled and followed for 3 years. Serum was drawn at the time of cardiac magnetic resonance (CMR). Normal biomarker values were derived from healthy subjects. Biomarkers were correlated with CMR markers. RESULTS: All subjects were asymptomatic at the time of enrollment. Several DMD subjects had transiently elevated cTnI. Those with elevated cTnI were more likely to have late gadolinium enhancement on baseline CMR. NT-proBNP correlated with indexed left ventricular end diastolic and maximum left atrial volumes. Otherwise, standard cardiac biomarkers did not correlate with CMR markers of cardiomyopathy. CONCLUSIONS: CTnI, BNP, and NT-proBNP do not correlate with CMR assessment of cardiomyopathy progression. A subset of DMD patients have asymptomatic cTnI leak of uncertain clinical significance, though of critical importance if cTnI is used to assess for cardiac toxicity in future drug trials. IMPACT: Asymptomatic patients with Duchenne muscular dystrophy (DMD) exhibit transient troponin I leak. NT-proBNP correlated with indexed left ventricular end diastolic volume and indexed maximum left atrial volume. Other cardiac biomarkers did not correlate with cardiac magnetic resonance (CMR) markers of cardiomyopathy.
BACKGROUND: Cardiomyopathy is the leading cause of death in Duchenne muscular dystrophy (DMD), but studies suggest heart failure biomarkers correlate poorly with cardiomyopathy severity. DMD clinical trials have used troponin I (cTnI) as a biomarker of toxicity, but it is unclear if asymptomatic DMD patients have elevated cTnI. We longitudinally evaluated cTnI, brain natriuretic peptide (BNP), and N-terminal pro-BNP (NT-proBNP) in a DMD cohort. METHODS: DMD patients were prospectively enrolled and followed for 3 years. Serum was drawn at the time of cardiac magnetic resonance (CMR). Normal biomarker values were derived from healthy subjects. Biomarkers were correlated with CMR markers. RESULTS: All subjects were asymptomatic at the time of enrollment. Several DMD subjects had transiently elevated cTnI. Those with elevated cTnI were more likely to have late gadolinium enhancement on baseline CMR. NT-proBNP correlated with indexed left ventricular end diastolic and maximum left atrial volumes. Otherwise, standard cardiac biomarkers did not correlate with CMR markers of cardiomyopathy. CONCLUSIONS: CTnI, BNP, and NT-proBNP do not correlate with CMR assessment of cardiomyopathy progression. A subset of DMD patients have asymptomatic cTnI leak of uncertain clinical significance, though of critical importance if cTnI is used to assess for cardiac toxicity in future drug trials. IMPACT: Asymptomatic patients with Duchenne muscular dystrophy (DMD) exhibit transient troponin I leak. NT-proBNP correlated with indexed left ventricular end diastolic volume and indexed maximum left atrial volume. Other cardiac biomarkers did not correlate with cardiac magnetic resonance (CMR) markers of cardiomyopathy.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jonathan H Soslow; Meng Xu; James C Slaughter; Kimberly Crum; Joshua D Chew; W Bryan Burnette; Yan Ru Su; Kelsey Tomasek; David A Parra; Larry W Markham Journal: J Card Fail Date: 2019-02-11 Impact factor: 5.712
Authors: E A P van Bockel; J S Lind; J G Zijlstra; P J Wijkstra; P M Meijer; M P van den Berg; R H J A Slart; L P H J Aarts; J E Tulleken Journal: Neth Heart J Date: 2009-06 Impact factor: 2.380
Authors: John Bourke; Cathy Turner; William Bradlow; Ashish Chikermane; Caroline Coats; Matthew Fenton; Maria Ilina; Alexandra Johnson; Stam Kapetanakis; Lisa Kuhwald; Adrian Morley-Davies; Ros Quinlivan; Konstantinos Savvatis; Marianela Schiava; Zaheer Yousef; Michela Guglieri Journal: Open Heart Date: 2022-10
Authors: Azher Arafah; Muneeb U Rehman; Ajaz Ahmad; Khalid M AlKharfy; Saeed Alqahtani; Basit L Jan; Nada M Almatroudi Journal: ACS Omega Date: 2022-01-25